TR006 Manufacturing
Cross-source consensus on TR006 Manufacturing from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Preparation
Highlighted claims
- The final TR006 product is cryopreserved and thawed at the bedside before administration. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Thymus tissue is collected before Basiliximab or other induction agents that could affect Treg function. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- TR006 manufacturing occurs at the GMP facility at Guy's Hospital. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Cryopreservation that preserves stability and function is framed as progress toward potential future off-the-shelf cell therapy. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)